NasdaqCM - Delayed Quote
USD
TG Therapeutics, Inc. (TGTX)
33.85
+0.07
(+0.21%)
At close: May 1 at 4:00:04 PM EDT
33.55
-0.30
(-0.89%)
After hours: May 1 at 6:44:43 PM EDT
Trade TGTX on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for TGTX
- Previous Close
33.78 - Open
33.86 - Bid 28.99 x 100
- Ask 38.18 x 100
- Day's Range
33.23 - 34.04 - 52 Week Range
25.28 - 40.99 - Volume
1,471,848 - Avg. Volume
1,879,559 - Market Cap (intraday)
5.405B - Beta (5Y Monthly) 1.75
- PE Ratio (TTM)
12.22 - EPS (TTM)
2.77 - Earnings Date May 6, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
44.57
Recent News: TGTX
View More
Performance Overview: TGTX
Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
TGTX
13.55%
S&P 500 (^GSPC)
5.62%
1-Year Return
TGTX
25.39%
S&P 500 (^GSPC)
29.01%
3-Year Return
TGTX
10.48%
S&P 500 (^GSPC)
73.47%
5-Year Return
TGTX
24.29%
S&P 500 (^GSPC)
72.92%
Earnings Trends: TGTX
View MoreAnalyst Insights: TGTX
View MoreStatistics: TGTX
View MoreValuation Measures
As of 5/1/2026
-
Market Cap
5.41B
-
Enterprise Value
5.52B
-
Trailing P/E
12.22
-
Forward P/E
35.97
-
PEG Ratio (5yr expected)
--
-
Price/Sales (ttm)
8.87
-
Price/Book (mrq)
8.34
-
Enterprise Value/Revenue
8.95
-
Enterprise Value/EBITDA
41.06
Financial Highlights
Profitability and Income Statement
-
Profit Margin
72.56%
-
Return on Assets (ttm)
9.39%
-
Return on Equity (ttm)
102.75%
-
Revenue (ttm)
616.29M
-
Net Income Avi to Common (ttm)
447.18M
-
Diluted EPS (ttm)
2.77
Balance Sheet and Cash Flow
-
Total Cash (mrq)
141.97M
-
Total Debt/Equity (mrq)
39.26%
-
Levered Free Cash Flow (ttm)
-43.98M
Compare To: TGTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights: TGTX
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports: TGTX
View More-
Lowering target price to $36.00
TG THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $36.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target -
Raising target price to $38.00
TG THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $38.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target -
Raising target price to $36.00
TG THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $36.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target -
What does Argus have to say about TGTX?
TG THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $35.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target
